Side-by-side comparison of AI visibility scores, market position, and capabilities
Unlearn.AI raised $50M+ for its digital twin technology that creates AI-generated control arms for clinical trials, reducing placebo group size and accelerating drug development timelines.
Unlearn.AI generates digital twins of clinical trial patients — AI models trained on historical trial data that predict how a specific patient would have responded as a placebo control. By supplementing small placebo control groups with these digital controls, pharmaceutical companies can run trials with fewer placebo patients (or none at all), reducing participant burden, trial costs, and development timelines without sacrificing statistical validity.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.